Patients and Patient Organizations Power Rare Disease Therapies

In an new article via PharmaVoice.com, “For most of the pharmaceutical industry, the focus on patient centricity is a relatively new phenomenon, and the industry continues to shift its focus to include patients as stakeholders when planning its marketing...

Allergan and AstraZeneca Commit to Antibiotic Development Deal

According to Genengnews.com, “Dublin-based Allergan has entered into an agreement with AstraZeneca to develop and commercialize a fixed-dose antibiotic formulation currently in Phase II study. The financial terms of the agreement were not detailed, though...